Significantly, the overexpression of PRMTs in cancer is often linked to poor prognosis [36, 37, 39, 40, 42, 44, 45], and PRMT inhibitors, especially against PRMT5, are currently being tested in clinical trials with cancer patients [52–56]. Here, PRMT5 is linked to cancer.